Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.59 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.50 |
| ▸ | VCP | P55072 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23540014 | 0.84 | VCP (0.69) | TRPV1VCPKDRALOX5KIF11 | |
| SCHEMBL22925921 | 0.84 | VCP (0.46) | TRPV1DEGS1VCPKDRALOX5 | |
| SCHEMBL29620940 | 0.84 | VCP (0.46) | TRPV1DEGS1VCPKDRALOX5 | |
| SCHEMBL22925556 | 0.84 | TRPV1 (0.55) | TRPV1VCPKDRALOX5FLT1 | |
| SCHEMBL22925774 | 0.81 | TRPV1 (0.48) | TRPV1VCPKDRFLT1FLT4 | |
| SCHEMBL29696305 | 0.81 | TRPV1 (0.47) | TRPV1KDRKIF11FLT1FLT4 | |
| SCHEMBL22926117 | 0.80 | TRPV1 (0.45) | TRPV1DEGS1VCPKDRALOX5 | |
| SCHEMBL22925553 | 0.80 | TRPV1 (0.49) | TRPV1VCPKDRALOX5FLT1 | |
| SCHEMBL22925559 | 0.79 | TRPV1 (0.49) | TRPV1VCPKDRALOX5FLT1 | |
| Hydrochloric Acid SCHEMBL31707411 | 0.79 | TRPV1 (0.45) | TRPV1DEGS1VCPKDRALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | TRPV1 4690/4885DEGS1 245/4885VCP 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.